<DOC>
	<DOC>NCT01614756</DOC>
	<brief_summary>The purpose of the study is to determine safety and tolerability of IL-31 mAB</brief_summary>
	<brief_title>A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis</brief_title>
	<detailed_description>Healthy Volunteers not acceptable for "Part 2" (Adult subjects with Atopic Dermatitis) Enrollment: (both Part 1 and Part 2) Part 2 will consist of up to 42 patients with atopic dermatitis</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Part 1: Healthy subjects Part 2: Adult subjects with: 1. Atopic dermatitis severity as assessed by Physician Global Assessment rating of 3 or higher (i.e., moderate or greater) on a scale of 0 to 5 2. Pruritus severity of at least 7 of 10 on a visual analog scale Receipt of systemic immunosuppressants, other than biological agents, or topical calcineurin inhibitors (tacrolimus or pimecrolimus) within 4 weeks prior to study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>